Please assess the completion status of the following clinical trial:

Trial Title: Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate with metastatic bone disease (by CT, MRI or bone scan) with plans to start or be \< 30 days from beginning androgen deprivation therapy. Patients with lymph node or visceral metastases only are not eligible~* Patients may receive palliative radiation therapy at the investigators discretion during the first 4 weeks of beginning protocol therapy.~Exclusion Criteria:~* No neuroendocrine, small cell or transitional cell cancer of the prostate No abnormal bone metabolism (i.e., Paget's disease, untreated hyperthyroidism, untreated hyperprolactinemia, untreated Cushing's disease).~* No use of calcitonin within 14 days before being registered for protocol therapy or any previous use of bisphosphonates.~* No major surgery within 4 weeks of registration to protocol therapy.~* No adjuvant chemotherapy within 6 months of registration to protocol therapy.~* No previous chemotherapy for metastatic disease.~* No hormonal therapy in the adjuvant setting within 12 months of registration to protocol therapy; previous hormonal therapy must not have exceeded 6 months.~* No prior history of malignancy in the past 5 years with the exception of basal cell and squamous cell carcinoma of the skin.~* No history of allergy or drug reactions to bisphosphonates.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Arm (Type: EXPERIMENTAL): Daily oral risedronate combined with androgen deprivation
- Placebo Arm (Type: PLACEBO_COMPARATOR): daily oral placebo combined with androgen deprivation

Based on this trial design, predict the completion outcome and termination type (if applicable).